Payment overview · 2025
General Payments
$684.08
31 reported records · 13 companies
Healthcare provider profile · identity verified
George Gray, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · VERO BEACH, FL · NPI 1790183168
Verified facts
What the public records show
CMS Open Payments records show George Gray, D.O. received $684.08 in general payments during 2025 across 31 reported records.
ABBVIE INC. accounted for 13.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Mounjaro, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.34 | 13.1% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $88.23 | 12.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $86.60 | 12.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.76 | 12.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $81.19 | 11.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.91 | 11.2% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $64.38 | 9.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.95 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.66 | 3.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.37 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.20 | 2.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.74 | 2.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.75 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $684.08 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $89.34 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $88.23 | 5 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $85.76 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $81.19 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.91 | 4 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $64.38 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $49.78 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.61 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.95 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 155 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 184 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
155 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
184 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 667 | 221 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 606 | 201 |
| Levothyroxine Sodium | Levothyroxine Sodium | 563 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 472 | 158 |
| Losartan Potassium | Losartan Potassium | 439 | 142 |
| Lisinopril | Lisinopril | 378 | 119 |
| Omeprazole | Omeprazole | 375 | 125 |
| Metformin Hcl | Metformin Hcl | 312 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 311 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 303 | 98 |
| Tamsulosin Hcl | Tamsulosin Hcl | 268 | 93 |
| Escitalopram Oxalate | Escitalopram Oxalate | 247 | 76 |
| Trazodone Hcl | Trazodone Hcl | 239 | 75 |
| Ezetimibe | Ezetimibe | 212 | 72 |
| Alprazolam | Alprazolam | 198 | 59 |
| Gabapentin | Gabapentin | 191 | 58 |
| Ozempic | Semaglutide | 184 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 63 |
| Simvastatin | Simvastatin | 159 | 46 |
| Mounjaro | Tirzepatide | 155 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 44 |
| Meloxicam | Meloxicam | 143 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 74 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 47 |
| Potassium Chloride | Potassium Chloride | 134 | 45 |
| Furosemide | Furosemide | 124 | 48 |
| Methylprednisolone | Methylprednisolone | 111 | 96 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 34 |
| Eliquis | Apixaban | 110 | 32 |
| Atenolol | Atenolol | 108 | 33 |
| Montelukast Sodium | Montelukast Sodium | 108 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 37 |
| Prednisone | Prednisone | 104 | 61 |
| Clonazepam | Clonazepam | 103 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 102 | 38 |
| Lorazepam | Lorazepam | 100 | 35 |
| Allopurinol | Allopurinol | 99 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 96 | 34 |
| Tramadol Hcl | Tramadol Hcl | 95 | 33 |
| Celecoxib | Celecoxib | 90 | 45 |
| Bupropion Xl | Bupropion Hcl | 82 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 29 |
| Azithromycin | Azithromycin | 81 | 70 |
| Carvedilol | Carvedilol | 81 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 80 | 71 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 80 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 19 |
| Jardiance | Empagliflozin | 75 | 29 |
| Finasteride | Finasteride | 70 | 22 |
| Alendronate Sodium | Alendronate Sodium | 68 | 23 |
| Sertraline Hcl | Sertraline Hcl | 68 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 56 |
| Famotidine | Famotidine | 64 | 22 |
| Valsartan | Valsartan | 64 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 17 |
| Synthroid | Levothyroxine Sodium | 47 | 15 |
| Valacyclovir | Valacyclovir Hcl | 46 | 21 |
| Nortriptyline Hcl | Nortriptyline Hcl | 42 | 20 |
| Azelastine Hcl | Azelastine Hcl | 41 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 13 |
| Olanzapine | Olanzapine | 41 | 19 |
| Fenofibrate | Fenofibrate | 40 | 12 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Diazepam | Diazepam | 39 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 11 |
| Spironolactone | Spironolactone | 36 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 13 |
| Myrbetriq | Mirabegron | 34 | 13 |
| Rybelsus | Semaglutide | 34 | 11 |
| Eszopiclone | Eszopiclone | 33 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | 15 |
| Benazepril Hcl | Benazepril Hcl | 30 | 11 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | 11 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 17 |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Gralise | Gabapentin | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | 11 |
| Epinephrine | Epinephrine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $684.08 · 31 records | ABBVIE INC. | AREXVY, CAPLYTA, Cologuard Collection Kit, GEMTESA, KEVEYIS, LEQVIO, MOUNJARO, Ozempic, QULIPTA, Repatha, SHINGRIX, SYNTHROID, UBRELVY, Veozah, WATCHMAN FLX, Wegovy, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error